

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Protein kinase C δ (PRKCD)	<p><i>In vitro</i> and mouse studies suggest PRKCD inhibitors could help prevent renal toxicity associated with cisplatin-based chemotherapy. In a rat renal proximal tubule cell line and in the kidneys of normal mice, cisplatin upregulated Prkcd activity compared with no treatment. In mouse models of cisplatin-induced renal toxicity and cisplatin-treated cancers, PRKCD inhibitors decreased kidney damage and renal failure compared with vehicle without compromising the antitumor effects of cisplatin. Future studies could include testing PRKCD inhibitors in other cisplatin-treated models of cancer.</p> <p>SciBX 4(23); doi:10.1038/scibx.2011.653 Published online June 9, 2011</p>	Patent and licensing status unavailable	<p>Pabla, N. <i>et al. J. Clin. Invest.</i>; published online June 1, 2011; doi:10.1172/JCI45586</p> <p>Contact: Zheng Dong, Medical College of Georgia and Charlie Norwood VA Medical Center, Augusta, Ga. e-mail: zdong@mail.mcg.edu</p>